Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp(IART)資訊與事件

$16.890

+0.041 (+0.24%)收盤時

IART 資訊

IART 事件

7/29 06:30

Integra LifeSciences Q2 Revenue $418.8M, Exceeds Expectations

Reports Q2 revenue $418.8M, consensus $417.54M. "Our Q2 performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year," said Stuart Essig, Chairman and CEO of Integra LifeSciences. "At the same time, we are seeing the benefits of a more aligned commercial organization while we continue to reduce our balance sheet leverage. Supported by our broad portfolio, attractive markets, and focused leadership team, we are strengthening our operating foundation and enhancing our ability to deliver sustainable long-term shareholder value."

7/29 06:30

Lowers FY26 Revenue Outlook to $1.654B-$1.695B

Lowers FY26 revenue view to $1.654B-$1.695B from $1.662B-$1.702B to reflect the impact of a stronger U.S. dollar on foreign exchange rates. Consensus is for FY26 revenue $1.68B.

7/29 06:30

Company Sees Q3 Revenue of $410M-$425M

Sees Q3 revenue $410M-$425M, consensus $417.43M. Q3 revenue view represents a reported growth of 2.0%-5.7% and organic growth of 1.9%-5.7%.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始